氯氮平
电休克疗法
精神分裂症(面向对象编程)
双相情感障碍
分裂情感障碍
重性抑郁障碍
医学
精神科
心理学
精神病
锂(药物)
认知
作者
Dara Gammon,Catherine Cheng,Anna Volkovinskaia,Glen B. Baker,Serdar Dursun
出处
期刊:Biomolecules
[MDPI AG]
日期:2021-07-15
卷期号:11 (7): 1030-1030
被引量:47
摘要
Clozapine is superior to other antipsychotics as a therapy for treatment-resistant schizophrenia and schizoaffective disorder with increased risk of suicidal behavior. This drug has also been used in the off-label treatment of bipolar disorder, major depressive disorder (MDD), and Parkinson's disease (PD). Although usually reserved for severe and treatment-refractory cases, it is interesting that electroconvulsive therapy (ECT) has also been used in the treatment of these psychiatric disorders, suggesting some common or related mechanisms. A literature review on the applications of clozapine and electroconvulsive therapy (ECT) to the disorders mentioned above was undertaken, and this narrative review was prepared. Although both treatments have multiple actions, evidence to date suggests that the ability to elicit epileptiform activity and alter EEG activity, to increase neuroplasticity and elevate brain levels of neurotrophic factors, to affect imbalances in the relationship between glutamate and γ-aminobutyric acid (GABA), and to reduce inflammation through effects on neuron-glia interactions are common underlying mechanisms of these two treatments. This evidence may explain why clozapine is effective in a range of neuropsychiatric disorders. Future increased investigations into epigenetic and connectomic changes produced by clozapine and ECT should provide valuable information about these two treatments and the disorders they are used to treat.
科研通智能强力驱动
Strongly Powered by AbleSci AI